Lucid Diagnostics Stock Alpha and Beta Analysis

LUCD Stock  USD 1.00  0.04  4.17%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lucid Diagnostics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lucid Diagnostics over a specified time horizon. Remember, high Lucid Diagnostics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lucid Diagnostics' market risk premium analysis include:
Beta
0.29
Alpha
0.21
Risk
2.84
Sharpe Ratio
0.12
Expected Return
0.33
Please note that although Lucid Diagnostics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Lucid Diagnostics did 0.21  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Lucid Diagnostics stock's relative risk over its benchmark. Lucid Diagnostics has a beta of 0.29  . As returns on the market increase, Lucid Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lucid Diagnostics is expected to be smaller as well. The current year's Book Value Per Share is expected to grow to -0.05. The current year's Tangible Book Value Per Share is expected to grow to -0.09.

Enterprise Value

52.47 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Lucid Diagnostics Backtesting, Lucid Diagnostics Valuation, Lucid Diagnostics Correlation, Lucid Diagnostics Hype Analysis, Lucid Diagnostics Volatility, Lucid Diagnostics History and analyze Lucid Diagnostics Performance.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Lucid Diagnostics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lucid Diagnostics market risk premium is the additional return an investor will receive from holding Lucid Diagnostics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lucid Diagnostics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lucid Diagnostics' performance over market.
α0.21   β0.29

Lucid Diagnostics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lucid Diagnostics' Buy-and-hold return. Our buy-and-hold chart shows how Lucid Diagnostics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Lucid Diagnostics Market Price Analysis

Market price analysis indicators help investors to evaluate how Lucid Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lucid Diagnostics shares will generate the highest return on investment. By understating and applying Lucid Diagnostics stock market price indicators, traders can identify Lucid Diagnostics position entry and exit signals to maximize returns.

Lucid Diagnostics Return and Market Media

The median price of Lucid Diagnostics for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 0.84 with a coefficient of variation of 9.6. The daily time series for the period is distributed with a sample standard deviation of 0.08, arithmetic mean of 0.87, and mean deviation of 0.07. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Lucid Diagnostics to be deconsolidated from PAVmeds financial statements
09/17/2024
2
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
10/08/2024
3
Avanos Medical Q3 Earnings Meet Estimates
10/30/2024
4
RxSight, Inc. Reports Break-Even Earnings for Q3
11/08/2024
5
Lucid Diagnostics Inc Q3 2024 Earnings Revenue Beats Estimates at 1. ...
11/13/2024
6
Lucid Diagnostics Inc Q3 2024 Earnings Call Highlights Record Revenue Growth Amid ...
11/14/2024
7
Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges
11/15/2024
8
Lucid Diagnostics SWOT analysis stock outlook amid reimbursement progress
11/21/2024

About Lucid Diagnostics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lucid or other stocks. Alpha measures the amount that position in Lucid Diagnostics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2010 2022 2023 2024 (projected)
Payables Turnover0.393.427.47.77
Days Of Inventory On Hand307.611.2111.9711.37

Lucid Diagnostics Upcoming Company Events

As portrayed in its financial statements, the presentation of Lucid Diagnostics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lucid Diagnostics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lucid Diagnostics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lucid Diagnostics. Please utilize our Beneish M Score to check the likelihood of Lucid Diagnostics' management manipulating its earnings.
12th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Lucid Diagnostics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out Lucid Diagnostics Backtesting, Lucid Diagnostics Valuation, Lucid Diagnostics Correlation, Lucid Diagnostics Hype Analysis, Lucid Diagnostics Volatility, Lucid Diagnostics History and analyze Lucid Diagnostics Performance.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Lucid Diagnostics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Lucid Diagnostics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Lucid Diagnostics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...